Zai Lab and argenx Report Positive Topline Data from ADHERE

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG...

Related Keywords

China ,Cambridge ,Cambridgeshire ,United Kingdom ,Huashan ,Henan ,Taiwan ,Shanghai ,Hong Kong ,Macau ,United States ,Christine Chiou ,Alina Zhang ,Harald Reinhart ,Demyelinating Polyneuropathy ,Shaun Maccoun Xiaoyu Chen ,Department Of Neurology ,Exchange Commission ,Zai Lab ,Head Of Global Development ,Zai Lab Forward ,Zai Lab Limited ,Huashan Hospital Affiliated To Fudan University ,Group Of Huashan Rare Disease Center ,Greater China ,Chongbo Zhao ,Deputy Director ,Huashan Hospital Affiliated ,Fudan University ,Working Group ,Huashan Rare Disease ,Global Development ,Infectious Diseases ,Inflammatory Neuropathy Cause ,Disability Score ,Inflammatory Rasch Built Overall Disability Scale ,Private Securities Litigation Reform Act ,Nasdaq Zlab ,